Work

Imaging with [ 89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: A phase 1/2, first-in-human trial.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15057

Authors: Salomon Tendler, Mark Dunphy, Anuradha Gopalan, Joseph A. O' Donoghue, Serge K. Lyashchenko, Lisa Bodei, Heiko Schöder, Karen A. Autio, John T. Poirier, Michael J. Morris, Charles M. Rudin, Jason S. Lewis

Institutions: Memorial Sloan Kettering Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Prostate Cancer Foundation

OpenAlex ID: W4410817407

FWCI: 1.09

Cites:

Cited by: 2

Related to: 10